Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - Concepedia

Concepedia

Publication | Open Access

Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer

DOI Full Paper Access

27

Citations

11

References

2021

Year

Ignace Vergote, Isabelle Ray‐Coquard, Daniel M. Anderson, Guilherme Cantuaria, Nicoletta Colombo, Claire Garnier-Tixidré, Lucy Gilbert, Philipp Harter, Robert Hettle, Domenica Lorusso,

European Journal of Cancer

Abstract

Results of this hypothesis-generating PA-ITC analysis support the use of maintenance olaparib alone or with bevacizumab in patients with newly diagnosed, advanced ovarian cancer and a BRCAm.

References

	Year	Citations

Page 1